142 related articles for article (PubMed ID: 1748682)
1. Early induction of ribonucleotide reductase gene expression by transforming growth factor beta 1 in malignant H-ras transformed cell lines.
Hurta RA; Samuel SK; Greenberg AH; Wright JA
J Biol Chem; 1991 Dec; 266(35):24097-100. PubMed ID: 1748682
[TBL] [Abstract][Full Text] [Related]
2. Malignant transformation by H-ras results in aberrant regulation of ribonucleotide reductase gene expression by transforming growth factor-beta 1.
Hurta RA; Wright JA
J Cell Biochem; 1995 Mar; 57(3):543-56. PubMed ID: 7768988
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor beta 1 selectively regulates ornithine decarboxylase gene expression in malignant H-ras transformed fibrosarcoma cell lines.
Hurta RA; Greenberg AH; Wright JA
J Cell Physiol; 1993 Aug; 156(2):272-9. PubMed ID: 8344985
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor beta1 selectively regulates ferritin gene expression in malignant H-ras-transformed fibrosarcoma cell lines.
Lo J; Hurta RA
Biochem Cell Biol; 2000; 78(4):527-35. PubMed ID: 11012093
[TBL] [Abstract][Full Text] [Related]
5. Transforming growth factor-beta 1 mediated alterations in ribonucleotide reductase gene expression in BALB/c 3T3 fibroblasts.
Hurta RA; Greenberg AH; Wright JA
J Cell Physiol; 1992 Sep; 152(3):529-35. PubMed ID: 1506411
[TBL] [Abstract][Full Text] [Related]
6. Transformation by H-ras can result in aberrant regulation of ornithine decarboxylase gene expression by transforming growth factor-beta(1).
Hurta RA; Lee J; Voskas D
J Cell Biochem; 2001; 81(1):39-55. PubMed ID: 11180396
[TBL] [Abstract][Full Text] [Related]
7. Alterations in the cyclic AMP signal transduction pathway regulating ribonucleotide reductase gene expression in malignant H-ras transformed cell lines.
Hurta RA; Wright JA
J Cell Physiol; 1994 Jan; 158(1):187-97. PubMed ID: 7505277
[TBL] [Abstract][Full Text] [Related]
8. A cis-trans interaction at the 3'-untranslated region of ribonucleotide reductase mRNA is regulated by TGF-beta 1, TGF-beta 2, and TGF-beta 3.
Amara FM; Smith GM; Kuschak TI; Takeuchi TL; Wright JA
Biochem Biophys Res Commun; 1996 Nov; 228(2):347-51. PubMed ID: 8920917
[TBL] [Abstract][Full Text] [Related]
9. Basic fibroblast growth factor selectively regulates ornithine decarboxylase gene expression in malignant H-ras transformed cells.
Hurta RA; Huang A; Wright JA
J Cell Biochem; 1996 Mar; 60(4):572-83. PubMed ID: 8707896
[TBL] [Abstract][Full Text] [Related]
10. Mammalian drug resistant mutants with multiple gene amplifications: genes encoding the M1 component of ribonucleotide reductase, the M2 component of ribonucleotide reductase, ornithine decarboxylase, p5-8, the H-subunit of ferritin and the L-subunit of ferritin.
Hurta RA; Wright JA
Biochim Biophys Acta; 1990 Oct; 1087(2):165-72. PubMed ID: 2223878
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of c-K-ras, c-N-ras and transforming growth factor beta co-segregate with tumorigenicity in morphologically transformed C3H 10T1/2 cell lines.
Coleman WB; Throneburg DB; Grisham JW; Smith GJ
Carcinogenesis; 1994 May; 15(5):1005-12. PubMed ID: 8200061
[TBL] [Abstract][Full Text] [Related]
12. A novel transforming growth factor-beta 1 responsive cytoplasmic trans-acting factor binds selectively to the 3'-untranslated region of mammalian ribonucleotide reductase R2 mRNA: role in message stability.
Amara FM; Chen FY; Wright JA
Nucleic Acids Res; 1993 Oct; 21(20):4803-9. PubMed ID: 8233829
[TBL] [Abstract][Full Text] [Related]
13. Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential.
Fan H; Villegas C; Wright JA
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14036-40. PubMed ID: 8943056
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations.
Choy BK; McClarty GA; Chan AK; Thelander L; Wright JA
Cancer Res; 1988 Apr; 48(8):2029-35. PubMed ID: 2832057
[TBL] [Abstract][Full Text] [Related]
15. Defining a novel cis element in the 3'-untranslated region of mammalian ribonucleotide reductase component R2 mRNA: role in transforming growth factor-beta 1 induced mRNA stabilization.
Amara FM; Chen FY; Wright JA
Nucleic Acids Res; 1995 May; 23(9):1461-7. PubMed ID: 7784197
[TBL] [Abstract][Full Text] [Related]
16. Correlation between levels of ferritin and the iron-containing component of ribonucleotide reductase in hydroxyurea-sensitive, -resistant, and -revertant cell lines.
Hurta RA; Wright JA
Biochem Cell Biol; 1991 Sep; 69(9):635-42. PubMed ID: 1793565
[TBL] [Abstract][Full Text] [Related]
17. Molecular and cellular characterization of drug resistant hamster cell lines with alterations in ribonucleotide reductase.
Tagger AY; Wright JA
Int J Cancer; 1988 Nov; 42(5):760-6. PubMed ID: 3053467
[TBL] [Abstract][Full Text] [Related]
18. Ribonucleotide reductase gene expression during cyclic AMP-induced cell cycle arrest in T lymphocytes.
Albert DA; Nodzenski E
Exp Cell Res; 1992 Dec; 203(2):476-82. PubMed ID: 1333983
[TBL] [Abstract][Full Text] [Related]
19. Tumour promoter mediated altered expression and regulation of ornithine decarboxylase and S-adenosylmethionine decarboxylase in H-ras-transformed fibrosarcoma cell lines.
Voskas D; Mader R; Lee J; Hurta RA
Biochem Cell Biol; 2001; 79(1):69-81. PubMed ID: 11235918
[TBL] [Abstract][Full Text] [Related]
20. Alterations in the activity and regulation of mammalian ribonucleotide reductase by chlorambucil, a DNA damaging agent.
Hurta RA; Wright JA
J Biol Chem; 1992 Apr; 267(10):7066-71. PubMed ID: 1551913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
